Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 693-702

  Sunder, Theodore R ^a   McKee, Jerry R ^b   Hammer, Anne E ^c   Vuong, Alain ^c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Western Carolina Center   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Community; Epilepsy; Institutional; Lamotrigine; Mental retardation; Resident

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ATAXIA; BEHAVIOR DISORDER; COMMUNITY; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; FEMALE; GRAND MAL SEIZURE; HUMAN; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; RATING SCALE; SEIZURE; SOMNOLENCE; TITRIMETRY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; ANTICONVULSANTS; DRUG TOLERANCE; EPILEPSY; FEMALE; HUMANS; INSTITUTIONALIZATION; MALE; MENTAL RETARDATION; MIDDLE AGED; RESIDENTIAL FACILITIES; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; TRIAZINES; UNITED STATES;

EID: 33646241301     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X96281     Document Type: Article

References (36)

1. Coulter DL. Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 1997;38(Suppl 4):S24-S31
2. Pellock J, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil 2000;6:309-23
3. Sunder TR. Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 1997;12(Suppl 1]:S38-S43
4. Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1988;42(Suppl 1):1-15
5. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9
6. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25
7. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63
8. Loiseau P, Yuen AWC, Duche B, et al. A randomized double-blind crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45
9. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91
10. Sander JW, Patsalos PN, Oxley JR, et al. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6
11. Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7
12. Frank LM, Enlow T, Holmes GL ,et al. Larnictal monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9
13. Matsuo F. Lamotrigine. Epilepsia 1999;40(Suppl 5):S30-S36
14. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. New Engl J Med 1997;337:1807-12
15. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7
16. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-6
17. Coppola G, Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Develop 1997;19:398-402
18. Gidal BE, Walker JK, Lott RS, et al. Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. Seizure 2000;9:131-6
19. Huber B, May T, Seidel M. Lamotrigine in multi-handicapped, therapy-resistant epileptic patients. Clin Drug Invest 1998;16:263-77
20. McKee JR, Sunder TR, FineSmith R, et al. Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. Epilepsy Behav 2003;4:386-94
21. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:305-7
22. Veggiotti P, Cieuta C, Rex E, et al. Lamotrigine in infantile spasms. Lancet 1994;344:1375-6
23. Stenbom Y, Tonnby B, Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry 1998;7:49-52
24. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 1993;24:339-40
25. Messenheimer JA, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998;18:281-96
26. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22
27. Coulter DL. Epilepsy and mental retardation: an overview. Am J Ment Retard 1993;98(Suppl):1-11
28. Singh BK, Towle PO. Antiepileptic drug status in adult outpatients with mental retardation. Am J Ment Retard 1993;98(Suppl):41-6
29. Vitello SJ, Atthowe Jr JM, Cadwell J. Determinants of community placement of institutionalized mentally retarded persons. Am J Ment Defic 1983;87:539-45
30. Mirza WU, Credeur LJ, Penry JK. Results of antiepileptic drug reduction in patients with multiple handicaps and epilepsy. Drug Invest 1993;5:320-6
31. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1989;30:389-99
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed [revised 1994]. Washington (DC): American Psychiatric Association; 1994
33. Aman MG, Singh NN, Turbott SH. Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. Am J Ment Defic 1987;92:237-40
34. Marshburn EC, Aman MG. Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992;22:357-73
35. Uvebrant P, Bauzien PR. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9
36. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88